Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome

被引:11
|
作者
Schofield, Jill R. [1 ,2 ]
Afrin, Lawrence B. [3 ]
机构
[1] Ctr Multisyst Dis, 8101 E Lowry Blvd, Denver, CO 80230 USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Armonk Integrat Med, Armonk, NY USA
来源
AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2019年 / 357卷 / 06期
关键词
Excipient; Mast cell activation syndrome; Postural tachycardia syndrome; Chemical sensitivity; Ehlers-Danlos syndrome;
D O I
10.1016/j.amjms.2019.03.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mast cell activation syndrome (MCAS) is a complex disorder hallmarked by chronic multisystem inflammatory, allergic and growth dystrophic phenomena caused by inappropriate mast cell activation. MCAS has been estimated to affect as many as 17% of the population with a severity ranging from mild to life-threatening. MCAS patients are more sensitive than the average person to chemicals in the environment, including the nondrug ("inactive") ingredients (excipients) in medications and supplements. Excipient reactivity may explain unusual side effects to medications health professionals often find puzzling, such as the patient who appears intolerant of prednisone, acetaminophen, levothyroxine, or a vitamin. We present a series of patients with MCAS to illustrate important points regarding excipient reactivity which may be useful in everyday practice.
引用
收藏
页码:507 / 511
页数:5
相关论文
共 50 条
  • [41] DERMATOMYOSITIS MASQUERADING AS MAST CELL ACTIVATION SYNDROME
    Chew, W.
    Schiopu, E.
    Kovalszki, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S84 - S84
  • [42] A CHALLENGING EVALUATION OF MAST CELL ACTIVATION SYNDROME
    Ganju, A.
    Yusin, J.
    Gianos, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S78 - S78
  • [43] OMALIZUMAB IN TREATMENT OF MAST CELL ACTIVATION SYNDROME
    Brown, R.
    Yao, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S86 - S87
  • [44] Mast Cell Activation Syndrome: A Primer for the Gastroenterologist
    Leonard B. Weinstock
    Laura A. Pace
    Ali Rezaie
    Lawrence B. Afrin
    Gerhard J. Molderings
    Digestive Diseases and Sciences, 2021, 66 : 965 - 982
  • [45] Utility of hydroxyurea in mast cell activation syndrome
    Afrin, Lawrence B.
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
  • [46] Mast cell activation syndrome: Myths and realities
    Zhang, Simin
    Bernstein, Jonathan A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2021, 42 (03) : 198 - 204
  • [47] Altered mast cell reactivity in patients with mastocytosis
    Gulen, T.
    Lyberg, K.
    Westerberg, Moeller C.
    Ekoff, M.
    Alexeyenko, A.
    Dahlen, B.
    Nilsson, G.
    ALLERGY, 2017, 72 : 445 - 445
  • [48] Mast Cell Activation Syndrome in Patients with Idiopathic CD4 Lymphopenia
    Maitland, Anne
    Reed, William
    Moreau, Joanne
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 383 - 383
  • [49] Reply to "Need to define a subgroup of patients with idiopathic mast cell activation syndrome"
    Gulen, Theo
    Akin, Cem
    Metcalfe, Dean D.
    Valent, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (04): : 1128 - 1128
  • [50] Restless legs syndrome is associated with mast cell activation syndrome
    Weinstock, Leonard B.
    Walters, Arthur S.
    Brook, Jill B.
    Kaleem, Zahid
    Afrin, Lawrence B.
    Molderings, Gerhard J.
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2020, 16 (03): : 401 - 408